Cargando…
Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features
An expanded hexanucleotide repeat in the C9ORF72 gene has recently been identified as a major cause of familial frontotemporal lobar degeneration and motor neuron disease, including cases previously identified as linked to chromosome 9. Here we present a detailed retrospective clinical, neuroimaging...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286330/ https://www.ncbi.nlm.nih.gov/pubmed/22366791 http://dx.doi.org/10.1093/brain/awr361 |
_version_ | 1782224539421245440 |
---|---|
author | Mahoney, Colin J. Beck, Jon Rohrer, Jonathan D. Lashley, Tammaryn Mok, Kin Shakespeare, Tim Yeatman, Tom Warrington, Elizabeth K. Schott, Jonathan M. Fox, Nick C. Rossor, Martin N. Hardy, John Collinge, John Revesz, Tamas Mead, Simon Warren, Jason D. |
author_facet | Mahoney, Colin J. Beck, Jon Rohrer, Jonathan D. Lashley, Tammaryn Mok, Kin Shakespeare, Tim Yeatman, Tom Warrington, Elizabeth K. Schott, Jonathan M. Fox, Nick C. Rossor, Martin N. Hardy, John Collinge, John Revesz, Tamas Mead, Simon Warren, Jason D. |
author_sort | Mahoney, Colin J. |
collection | PubMed |
description | An expanded hexanucleotide repeat in the C9ORF72 gene has recently been identified as a major cause of familial frontotemporal lobar degeneration and motor neuron disease, including cases previously identified as linked to chromosome 9. Here we present a detailed retrospective clinical, neuroimaging and histopathological analysis of a C9ORF72 mutation case series in relation to other forms of genetically determined frontotemporal lobar degeneration ascertained at a specialist centre. Eighteen probands (19 cases in total) were identified, representing 35% of frontotemporal lobar degeneration cases with identified mutations, 36% of cases with clinical evidence of motor neuron disease and 7% of the entire cohort. Thirty-three per cent of these C9ORF72 cases had no identified relevant family history. Families showed wide variation in clinical onset (43–68 years) and duration (1.7–22 years). The most common presenting syndrome (comprising a half of cases) was behavioural variant frontotemporal dementia, however, there was substantial clinical heterogeneity across the C9ORF72 mutation cohort. Sixty per cent of cases developed clinical features consistent with motor neuron disease during the period of follow-up. Anxiety and agitation and memory impairment were prominent features (between a half to two-thirds of cases), and dominant parietal dysfunction was also frequent. Affected individuals showed variable magnetic resonance imaging findings; however, relative to healthy controls, the group as a whole showed extensive thinning of frontal, temporal and parietal cortices, subcortical grey matter atrophy including thalamus and cerebellum and involvement of long intrahemispheric, commissural and corticospinal tracts. The neuroimaging profile of the C9ORF72 expansion was significantly more symmetrical than progranulin mutations with significantly less temporal lobe involvement than microtubule-associated protein tau mutations. Neuropathological examination in six cases with C9ORF72 mutation from the frontotemporal lobar degeneration series identified histomorphological features consistent with either type A or B TAR DNA-binding protein-43 deposition; however, p62-positive (in excess of TAR DNA-binding protein-43 positive) neuronal cytoplasmic inclusions in hippocampus and cerebellum were a consistent feature of these cases, in contrast to the similar frequency of p62 and TAR DNA-binding protein-43 deposition in 53 control cases with frontotemporal lobar degeneration–TAR DNA-binding protein. These findings corroborate the clinical importance of the C9ORF72 mutation in frontotemporal lobar degeneration, delineate phenotypic and neuropathological features that could help to guide genetic testing, and suggest hypotheses for elucidating the neurobiology of a culprit subcortical network. |
format | Online Article Text |
id | pubmed-3286330 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-32863302012-02-27 Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features Mahoney, Colin J. Beck, Jon Rohrer, Jonathan D. Lashley, Tammaryn Mok, Kin Shakespeare, Tim Yeatman, Tom Warrington, Elizabeth K. Schott, Jonathan M. Fox, Nick C. Rossor, Martin N. Hardy, John Collinge, John Revesz, Tamas Mead, Simon Warren, Jason D. Brain Original Articles An expanded hexanucleotide repeat in the C9ORF72 gene has recently been identified as a major cause of familial frontotemporal lobar degeneration and motor neuron disease, including cases previously identified as linked to chromosome 9. Here we present a detailed retrospective clinical, neuroimaging and histopathological analysis of a C9ORF72 mutation case series in relation to other forms of genetically determined frontotemporal lobar degeneration ascertained at a specialist centre. Eighteen probands (19 cases in total) were identified, representing 35% of frontotemporal lobar degeneration cases with identified mutations, 36% of cases with clinical evidence of motor neuron disease and 7% of the entire cohort. Thirty-three per cent of these C9ORF72 cases had no identified relevant family history. Families showed wide variation in clinical onset (43–68 years) and duration (1.7–22 years). The most common presenting syndrome (comprising a half of cases) was behavioural variant frontotemporal dementia, however, there was substantial clinical heterogeneity across the C9ORF72 mutation cohort. Sixty per cent of cases developed clinical features consistent with motor neuron disease during the period of follow-up. Anxiety and agitation and memory impairment were prominent features (between a half to two-thirds of cases), and dominant parietal dysfunction was also frequent. Affected individuals showed variable magnetic resonance imaging findings; however, relative to healthy controls, the group as a whole showed extensive thinning of frontal, temporal and parietal cortices, subcortical grey matter atrophy including thalamus and cerebellum and involvement of long intrahemispheric, commissural and corticospinal tracts. The neuroimaging profile of the C9ORF72 expansion was significantly more symmetrical than progranulin mutations with significantly less temporal lobe involvement than microtubule-associated protein tau mutations. Neuropathological examination in six cases with C9ORF72 mutation from the frontotemporal lobar degeneration series identified histomorphological features consistent with either type A or B TAR DNA-binding protein-43 deposition; however, p62-positive (in excess of TAR DNA-binding protein-43 positive) neuronal cytoplasmic inclusions in hippocampus and cerebellum were a consistent feature of these cases, in contrast to the similar frequency of p62 and TAR DNA-binding protein-43 deposition in 53 control cases with frontotemporal lobar degeneration–TAR DNA-binding protein. These findings corroborate the clinical importance of the C9ORF72 mutation in frontotemporal lobar degeneration, delineate phenotypic and neuropathological features that could help to guide genetic testing, and suggest hypotheses for elucidating the neurobiology of a culprit subcortical network. Oxford University Press 2012-03 2012-02-24 /pmc/articles/PMC3286330/ /pubmed/22366791 http://dx.doi.org/10.1093/brain/awr361 Text en © The Author (2012). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Mahoney, Colin J. Beck, Jon Rohrer, Jonathan D. Lashley, Tammaryn Mok, Kin Shakespeare, Tim Yeatman, Tom Warrington, Elizabeth K. Schott, Jonathan M. Fox, Nick C. Rossor, Martin N. Hardy, John Collinge, John Revesz, Tamas Mead, Simon Warren, Jason D. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features |
title | Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features |
title_full | Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features |
title_fullStr | Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features |
title_full_unstemmed | Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features |
title_short | Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features |
title_sort | frontotemporal dementia with the c9orf72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286330/ https://www.ncbi.nlm.nih.gov/pubmed/22366791 http://dx.doi.org/10.1093/brain/awr361 |
work_keys_str_mv | AT mahoneycolinj frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT beckjon frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT rohrerjonathand frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT lashleytammaryn frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT mokkin frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT shakespearetim frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT yeatmantom frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT warringtonelizabethk frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT schottjonathanm frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT foxnickc frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT rossormartinn frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT hardyjohn frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT collingejohn frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT revesztamas frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT meadsimon frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures AT warrenjasond frontotemporaldementiawiththec9orf72hexanucleotiderepeatexpansionclinicalneuroanatomicalandneuropathologicalfeatures |